Cost Offsets Crucial For Uptake Of Advanced Therapies
Companies That Fail To Adapt Risk Deterring Investment
Executive Summary
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.
You may also be interested in...
German HTA: Clinical Cancer Registries Could Hold Key To Better Comparative Data For Benefit Assessments
Better data linkage and data entry systems could transform Germany’s clinical cancer registries into a reliable data source for health technology assessments.
European Health Data Space Talks Falter Over Opt-Out Issue
The pharmaceutical industry has warned co-legislators against any hasty compromises that could impact the competitiveness of EU research.
Germany’s Confidential Pricing Move Could Protect Companies From Potential Trumpian US Reference Pricing
Confidential pricing would give companies more flexibility to negotiate discounts and prevent withdrawals.